Roquette Showcases Scalable Drug Delivery Innovations at CPHI China 2026
核心洞察
Roquette will present its expanded portfolio of pharmaceutical excipients and drug delivery solutions at CPHI & PMEC China 2026 in Shanghai from June 16-18.
The company's PEARLITOL® mannitol (搜索), manufactured in China, enables high and low dose formulations across oral, injectable, inhalation, and biologic applications with enhanced stability.
Angela Strzelecki, CEO of Roquette's Health & Pharma Solutions, emphasized the growing industry pressure for manufacturing reliability and robust formulations at scale, particularly for GLP-1 therapies and complex biologics.
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, will showcase its comprehensive portfolio of innovative drug delivery solutions at CPHI & PMEC China 2026, taking place June 16-18 at the Shanghai New International Expo Centre (SNIEC). Under the theme "One Roquette for Innovations," the company's Health & Pharma Solutions Business Unit will exhibit at booth E3D26, highlighting how its deep scientific expertise and technical capabilities enable pharmaceutical companies to turn promising formulations into scalable commercial realities.
"As the pharmaceutical industry accelerates innovation, from GLP-1 therapies to complex biologics, the pressure to deliver manufacturing reliability, consistent supply, and robust formulations at scale has never been greater," said Angela Strzelecki, Senior Vice President of the Roquette Group and CEO of Roquette's Health & Pharma Solutions Business Unit. "At Roquette, we are uniquely positioned to address these challenges through our integrated portfolio spanning excipients, formulation technologies, biopharmaceutical solutions, and hard capsules. With a wide manufacturing network and global quality standards, we are committed to being the trusted partner that powers the next generation of drug delivery in China and the Asia Pacific region."
PEARLITOL® Mannitol: Enabling Scalable, Modern Drug Delivery
A centerpiece of Roquette's exhibit will be PEARLITOL® mannitol (搜索), a versatile excipient designed to simplify formulation development while maintaining exceptional performance at scale. Manufactured in China to support reliable regional supply, PEARLITOL® mannitol enables high and low dose formulations across a wide range of dosage forms, enhanced stability in sensitive conditions, reliable processability and batch-to-batch consistency, and flexibility across oral, injectable, inhalation, and biologic applications.
Integrated Solutions for Every Stage of Drug Development
Roquette's booth will feature its complete range of pharmaceutical solutions designed to address the industry's most pressing challenges. The company's high-performance pharmaceutical excipients include Avicel® microcrystalline cellulose, Ac-Di-Sol® croscarmellose sodium, METHOCEL™ HPMC, ETHOCEL™ ethylcellulose, and POLYOX™ polyethylene oxide. Differentiated formulation technologies span oral solid dosage forms, controlled release systems, and complex specialty formulations.
In the biopharmaceutical space, Roquette offers KLEPTOSE® beta-cyclodextrins (搜索) for protein stabilization and NOVAMATRIX-3D™ alginate foams for 3D cell culture. Through its Qualicaps (搜索) division, the company provides a full range of HPMC and gelatin capsules for oral and inhalation applications. End-to-end support extends from early formulation development through to commercial manufacturing scale-up.
Roquette is a family-owned company with over 90 years of expertise and 11,000 employees, serving clients in over 150 countries. The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.